NCT03428373View on ClinicalTrials.gov

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

December 1, 2023

Study Completion Date

September 30, 2024

Conditions
Multiple Myeloma in RelapseMultiple Myeloma ProgressionMultiple Myeloma Stage IIMultiple Myeloma Stage IMultiple Myeloma With Failed RemissionMultiple Myeloma Stage III
Interventions
DRUG

Rivaroxaban

Rivaroxaban 10mg daily

DRUG

ASA

ASA 81mg

Trial Locations (1)

N6A 5W9

London Health Sciences Centre, London

All Listed Sponsors
collaborator

The Ottawa Hospital

OTHER

collaborator

Dalhousie University

OTHER

collaborator

Niagara Health System

OTHER

collaborator

Hamilton Health Sciences Corporation

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT03428373 - Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma | Biotech Hunter | Biotech Hunter